1994
DOI: 10.1093/oxfordjournals.annonc.a058729
|View full text |Cite
|
Sign up to set email alerts
|

Extrapulmonary small cell carcinoma: A single-institution experience and review of the literature

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
7
0
1

Year Published

1998
1998
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 86 publications
(9 citation statements)
references
References 32 publications
1
7
0
1
Order By: Relevance
“…A small percentage of cases presented as a composite tumor ( n = 22; 5.0%) with features of both NCL and squamous cell carcinoma on histological examination. The vast majority of these patients had small‐cell neuroendocrine carcinoma ( n = 20; 90.9%) . The other 2 cases concerned an atypical and an unspecified carcinoid tumor …”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…A small percentage of cases presented as a composite tumor ( n = 22; 5.0%) with features of both NCL and squamous cell carcinoma on histological examination. The vast majority of these patients had small‐cell neuroendocrine carcinoma ( n = 20; 90.9%) . The other 2 cases concerned an atypical and an unspecified carcinoid tumor …”
Section: Resultsmentioning
confidence: 99%
“…The literature on NCL is fragmented over numerous case reports and series of small sample size, often with contradicting results, making it difficult to decide on an appropriate treatment strategy. Consequently, physicians facing these tumors often resort to treatment paradigms developed for better known neoplasms (eg, squamous cell carcinoma).…”
Section: Introductionmentioning
confidence: 99%
“…Combination cisplatin and etoposide (EP) is a commonly used regimen for EPSCC with a response rates reported, in extensive disease, as 50% to 70%. It remains the cornerstone of therapy in SCLC [ 4 , 5 , 15 ]. In the first line setting single agent topotecan and paclitaxel have shown to be possible therapeutic options.…”
Section: Discussionmentioning
confidence: 99%
“…First described by Duguid and Kennedy in 1930 [ 1 , 2 ] EPSCC is recognized as a clinicopathologic entity distinct from small cell lung carcinoma [ 3 - 5 ]. Small cell carcinomas arising outside the lung have been reported in almost every organ of the body [ 5 - 7 ].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation